Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex Incorporated (NYSE: TFX) announced multiple clinical studies at the 2024 American Urological Association Annual Meeting, showcasing the UroLift™ System to treat benign prostatic hyperplasia. The studies include head-to-head RCT data presentations, post-surgery medication use analysis, and real-world evidence studies.
Teleflex Incorporated has announced the market release of the Wattson™ Temporary Pacing Guidewire, expanding its structural heart portfolio. The device offers dual functionality, supporting valve delivery and ventricular pacing during procedures like TAVR and BAV. Designed to reduce complications, costs, and procedural steps associated with traditional pacing methods, the guidewire aims to enhance procedural efficiency and safety.
Teleflex Incorporated (NYSE: TFX) Chairman, President, and CEO Liam Kelly will present at the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. The live audio webcast will be accessible on the Teleflex website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
